Compare Gap Inc (GAP) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Inovio Pharmaceuticals Inc — how do they compare? Gap Inc trades at $23.33 (market cap $8.29B), while Inovio Pharmaceuticals Inc trades at $1.11 (market cap $119.42M). The key difference: Gap Inc is far larger — about 69.4× Inovio Pharmaceuticals Inc's market cap, and Gap Inc pays a 2.96% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| GAP | INO | |
|---|---|---|
Market Cap | $8.29B | $119.42M |
Volume | 5,470,564 | 2,789,649 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $2.65 |
52-Week Low | $18.35 | $0.66 |
Typical Hold Time | 37 Days | 43 Days |
Enterprise Value | $11.53B | $90.75M |
Dividend Yield | 2.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap trades at $23.36, down 1.81% for the day, with a bullish technical outlook from moving averages. The company shows strong profitability with a 43.26% gross margin and 8.14% net margin, supported by recent earnings beats. Revenue has stabilized around $15B, and cash flow from operations remains robust at $1.49B. Recent news highlights brand revitalization efforts, including music partnerships and board appointments, signaling strategic moves to engage customers.
The outlook is positive given low valuations (P/E 7.11, P/S 0.58) and analyst consensus target of $25.67, implying upside. Risks include reliance on Old Navy's turnaround and competitive pressures. Institutional activity is mixed, with some funds reducing stakes while others increase positions, reflecting cautious optimism.
INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.
The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
